

In the matter of the Canadian Anti-Doping Program;

**And in the matter of an Anti-Doping Rule Violation by Scott Lieph asserted by the
Canadian Centre for Ethics in Sport;**

File Outcome Summary

Summary

1. The Canadian Centre for Ethics in Sport (CCES) conducted an Out-of-Competition sample collection session on March 22, 2022, in Sooke, BC.
2. Mr. Scott Lieph (“the Athlete”) was selected for doping control. The sample provided by the Athlete returned an adverse analytical finding for Mesterolone and Oxandrolone, both of which are non-specified prohibited substances.
3. Following receipt of the CCES’ Notice of Charge, asserting an Anti-Doping Rule Violation (“ADRV”) for the Presence and Use of Mesterolone and Oxandrolone, the Athlete signed an Early Admission and Acceptance Form thereby admitting the ADRV, waiving his right to a hearing and accepting all proposed consequences.

Jurisdiction

4. The CCES is an independent not-for-profit organization incorporated under the federal laws of Canada that promotes ethical conduct in all aspects of sport in Canada. The CCES also maintains and carries out the CADP, including providing anti-doping services to national sport organizations and their members.
5. As Canada’s national anti-doping organization, the CCES is in compliance with the World Anti-Doping Code (Code) and its mandatory International Standards. The CCES has implemented the Code and its mandatory International Standards through the CADP, the domestic rules which govern this proceeding. The purpose of the Code and of the CADP is to protect the rights of athletes to fair competition.
6. The Athlete is a member of Softball Canada. According to Part C, Rule 1.3 of the CADP, the CADP provisions apply to all members of, and participants in the activities of, sport organizations adopting it. The CADP was adopted by Softball Canada on November 4, 2020. Therefore, as a member of Softball Canada and/or as a participant in Softball Canada sport activities, the Athlete is subject to the Rules of the CADP.

Doping Control

7. On March 22, 2022, the CCES conducted an Out-of-Competition doping control session in Sooke, BC. Testing was conducted on softball athletes as part of the CCES’ domestic test distribution plan, all pursuant to the CADP.
8. The Athlete was notified for doping control and, together with the Doping Control Officer (DCO) from the CCES, completed the sample collection process. The Athlete’s sample code number was 4625776.
9. On March 25, 2022, the Athlete’s sample was received by the World Anti-Doping Agency (WADA) accredited laboratory, the INRS-Institut Armand-Frappier (INRS), in Laval, QC.

Results Management

10. The adverse analytical finding was received from the INRS on April 13, 2022. The Certificate of Analysis indicated the presence of Mesterolone and Oxandrolone.
11. Mesterolone and Oxandrolone are classified as non-specified prohibited substances on the 2022 WADA Prohibited List.
12. On May 4, 2022, the CCES issued a Notification regarding the Athlete's adverse analytical finding.
13. On May 26, 2022, the CCES issued a Notice of Charge formally asserting a violation against the Athlete for the Presence and Use of two prohibited substances. Within the Notice of Charge, the CCES also imposed a Provisional Suspension on the athlete in accordance with CADP Rule 7.4.1
14. In accordance with CADP Rule 10.2.1, the standard sanction for an anti-doping violation involving the Presence of a non-specified prohibited substances is a four (4) year period of ineligibility. The CCES proposed the standard four (4) year sanction within its Notice of Charge of May 26, 2022.

Confirmation of Violation and Sanction

15. In accordance with CADP Rule 10.8.1, which was specifically referenced within the Notice of Charge, the CCES informed the Athlete on May 26, 2022, that should the Athlete exercise their option to sign the Early Admission and Acceptance Form, the Athlete would receive a one (1) year reduction in the four (4) year period of ineligibility asserted by the CCES.
16. On June 13, 2022, the Athlete signed and submitted the Early Admission and Acceptance Form to the CCES. Accordingly, effective June 13, 2022, an ADRV has been confirmed against the Athlete for the presence of the identified prohibited substances. In accordance with CADP Rules 10.2.1, 7.4.1, 10.13.2.1 and 10.8.1, the sanction for this violation is a three (3) year period of ineligibility which commences on May 26, 2022, (the date the athlete was provisionally suspended) and concludes on May 25, 2025. Further, in accordance with CADP Rule 10.10, any competitive results obtained by the Athlete, from date of sample collection, must be disqualified.
17. The CCES now considers this case closed.

Dated at Ottawa, Ontario this 4th day of July 2022.



Jeremy Luke
Executive Director, Sport Integrity
CCES